News

The US Food and Drug Administration (FDA) has granted accelerated approval for a new drug for certain patients with neuroblastoma based on response rate results in small open-label trials. The drug is naxitamab (Danyelza, Y-mAbs Therapeutics), a humanized monoclonal antibody that targets GD2 3F8, a disialoganglioside highly expressed on neuroblastomas. The product was originally developed at the
0 Comments
With three drug companies on the verge of a breakthrough vaccine against Covid-19, vaccinations could begin by the end of December, said Anthony Fauci, MD, yesterday in a live interview with the Washington Post. And while the first shots will go to high-risk and priority populations, Dr. Fauci, director of the National Institute of Allergy
0 Comments
Ladies, some advice on online dating: the old real estate adage of location, location, location, applies.  “If you’re a woman, you probably want to start on Match.com because it is a little bit like Target,” said Andrea McGinty, matchmaker and owner of 33,000Dates.com. “It has everything, from a high end, upscale group of professionals to everything imaginable.”
0 Comments
When the first batch of Covid-19 vaccine becomes available, it will go to states based on the total number of adults living in each state, officials from Operation Warp Speed said, according to National Public Radio.  Once the Food and Drug Administration (FDA) gives regulatory clearance, the federal government said that it will ship out
0 Comments
Although Thanksgiving, and the holidays that follow, might be billed as a time of indulgence — with creamy pumpkin pie, buttery rolls and plenty of egg nog — a little indulgence might not be a bad idea. Instead of trying to lose weight or being “good” this year, experts suggest taking care of yourself, even
0 Comments
The holidays are approaching just as COVID-19 case rates nationwide are increasing at a record-breaking pace, leading to dire warnings from public health experts. The Centers for Disease Control and Prevention has issued cautions and updated guidelines related to family gatherings. Dr. Anthony Fauci, a White House coronavirus adviser and director of the National Institute of Allergy
0 Comments
Heart failure could be reversed with a new treatment that combines medication with the temporary use of an artificial heart pump, said researchers at the University of Utah Health.  The therapy, which involves implantation of a left ventricular assist device ( LVAD ), could: help reverse structural damage to the heart, eliminate the need for
0 Comments
Immunotherapy with pembrolizumab holds promise for improving the generally dismal outlook in patients with leptomeningeal metastases, a phase 2 trial suggests. Results from the trial were reported at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting. “Unfortunately, when patients present with leptomeningeal disease, they usually have a poor prognosis. Their median survival is
0 Comments
Healthcare workers and residents of long-term care facilities may be first in line to get the COVID-19 vaccine, followed by essential workers and then adults with high-risk medical conditions and older adults, members of the CDC’s Advisory Committee on Immunization Practices (ACIP) agreed during a Monday meeting. These new groups would be phase 1a, phase
0 Comments
Coronavirus cases are spiking across the country, and local and state governments are trying to curb the spread.  Here’s a synopsis of pandemic-created changes to review as we head into winter and the holiday season. In most cities, expect indoor dining to no longer be an option — it’s already happened in Philadelphia and St.
0 Comments
After many years of good management of their high blood pressure, Americans are letting that control slip: the number of Americans with uncontrolled blood pressure rates has been rising. And while this trend has been creeping up since 2015, Covid-19, as with most things today, seems to have left its mark.   These increasing numbers aren’t
0 Comments
Combination treatment with the investigational, selective KIT inhibitor PLX9486 plus sunitinib (Sutent) was safe and active in patients with relapsed or refractory gastrointestinal stromal tumors (GIST), a small phase I/II study found. Among 18 patients treated with the combination, one achieved a complete response, two had partial responses, and another had an unconfirmed partial response,
0 Comments
The full 5-year results of a long-term extension study of tildrakizumab for psoriasis show a high rate of sustained disease control coupled with a favorable safety profile during more than 5,400 patient-years of prospective follow-up, Diamont Thaçi, MD, PhD, reported at the virtual annual congress of the European Academy of Dermatology and Venereology. For example, 89% of
0 Comments
Many of us are frittering away time on Facebook or Twitter as we hunker down at home during the pandemic. But there’s a potential upside to all this social media engagement: It lets public health officials know how people feel about Covid-19 restrictions and can be used to encourage compliance. Australian researchers found that social
0 Comments
A novel algorithm-based disease management program, led by pharmacists and nonlicensed navigators, optimized cholesterol and blood pressure levels in high-risk patients, according to an interim report from the first 5000 patients. Mean low-density lipoprotein cholesterol (LDL-C) levels fell from 125 mg/dL to 73 mg/dL among those who finished active treatment titration and from 133 mg/dL
0 Comments
Treatment with an investigational albumin-bound mTOR inhibitor showed long-lasting responses in patients with advanced malignant perivascular epithelioid cell tumors (PEComa), extended follow-up from the single-arm AMPECT study showed. On independent review, the overall response rate (ORR) with nab-sirolimus in 31 malignant PEComa patients was 39% (95% CI 22-58), including one complete response, meeting the primary
0 Comments
The interventional cardiology community is mourning the loss of Prof Anthony “Tony” Gershlick, MBBS, who died November 20 of COVID-19. He was 69. Gershlick was a “talented, dedicated and much loved colleague,” reads a statement issued by the University of Leicester, where he was affiliated for more than three decades. Gershlick, a consultant cardiologist at
0 Comments